All In Biotech

Drug Trial Radar · NCT07937605

KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer

A Phase II Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetic Characteristics of KC1086 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2029

Study completion Nov 2030

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of KC1086 in combination with fulvestrant in adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.

Conditions

  • HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Interventions

  • KC1086Drug

    Dosage: 1 mg, 2 mg, or 4 mg; Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.

  • FulvestrantDrug

    Dose: 500 mg. Route: intramuscular injection. Frequency: on Day 1 and Day 15 of Cycle 1, then on Day 1 of each cycle from Cycle 2 onward, 28 days as a cycle.

  • Everolimus (10 mg QD)Drug

    Dose: 10 mg. Route: oral, with or without food. Frequency: once daily, 28 days as a cycle.

  • ExemestaneDrug

    Dose: 25 mg. Route: oral, after a meal. Frequency: once daily, 28 days as a cycle.

  • KC1086Drug

    Dosage: based on the doses selected in Part 1 (high dose and low dose); Route: Oral; Frequency: Once daily (QD) under fasting conditions (at least 2 hours before and 1 hour after dosing), 28 days as a cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Baseline to study completion (approximately 48 months)
  2. Adverse events (AEs)Time frame: Baseline to study completion (approximately 48 months)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.